{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:52:01Z","timestamp":1791341521690,"version":"4.3.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":96,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010108","name":"Zhongshan Hospital","doi-asserted-by":"publisher","award":["2016ZSL-06"],"award-info":[{"award-number":["2016ZSL-06"]}],"id":[{"id":"10.13039\/501100010108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-05009-1","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:26:12Z","timestamp":1783085172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of leflunomide in active Takayasu arteritis: a randomized double-blind placebo-controlled trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Ying","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufang","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"5009_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/BOR.0000000000000852","volume":"34","author":"SN Esatoglu","year":"2022","unstructured":"Esatoglu SN, Hatemi G. Takayasu arteritis. Curr Opin Rheumatol. 2022;34:18\u201324.","journal-title":"Curr Opin Rheumatol"},{"key":"5009_CR2","doi-asserted-by":"publisher","first-page":"4982","DOI":"10.1093\/rheumatology\/keab406","volume":"60","author":"M Rutter","year":"2021","unstructured":"Rutter M, Bowley j, Lanyon PC, Grainge MJ, Pearce FA. A systematic review and meta-analysis of the incidence rate of Takayasu arteritis. Rheumatology (Oxford). 2021;60:4982\u201390.","journal-title":"Rheumatology (Oxford)"},{"key":"5009_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41584-021-00718-8","volume":"18","author":"RA Watts","year":"2022","unstructured":"Watts RA, Hatemi G, Burns JC, Mohammad AJ. Global epidemiology of vasculitis. Nat Rev Rheumatol. 2022;18:22\u201334.","journal-title":"Nat Rev Rheumatol"},{"key":"5009_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1253\/circj.CJ-23-0656","volume":"88","author":"H Yoshifuji","year":"2024","unstructured":"Yoshifuji H, Nakaoka Y, Uchida HA, Sugihara T, Watanabe Y, Funakoshi S, et al. Organ damage and quality of life in Takayasu arteritis \u2013 evidence from a national registry analysis. Circ J. 2024;88:285\u201394.","journal-title":"Circ J"},{"key":"5009_CR5","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1093\/rheumatology\/kead584","volume":"63","author":"S Jagtap","year":"2024","unstructured":"Jagtap S, Mishra P, Rathore U, Thakare DR, Singh K, Dixit J, et al. Increased mortality rate in Takayasu arteritis is largely driven by cardiovascular disease-a cohort study. Rheumatology (Oxford). 2024;63:3337\u201345.","journal-title":"Rheumatology (Oxford)"},{"key":"5009_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaut.2018.08.001","volume":"96","author":"A Mirouse","year":"2019","unstructured":"Mirouse A, Biard L, Comarmond C, Lambert M, Mekinian A, Ferfar Y, et al. Overall survival and mortality risk factors in Takayasu\u2019s arteritis: a multicenter study of 318 patients. J Autoimmun. 2019;96:35\u20139.","journal-title":"J Autoimmun"},{"key":"5009_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11926-020-00963-y","volume":"22","author":"MJ Koster","year":"2020","unstructured":"Koster MJ, Warrington KJ, Matteson EL. Morbidity and mortality of large-vessel vasculitides. Curr Rheumatol Rep. 2020;22:86.","journal-title":"Curr Rheumatol Rep"},{"key":"5009_CR8","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/art.41774","volume":"73","author":"M Maz","year":"2021","unstructured":"Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology\/Vasculitis foundation guideline for the management of Giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol. 2021;73:1349\u201365.","journal-title":"Arthritis Rheumatol"},{"key":"5009_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79:19\u201330.","journal-title":"Ann Rheum Dis"},{"key":"5009_CR10","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s00296-021-04958-5","volume":"41","author":"DP Misra","year":"2021","unstructured":"Misra DP, Rathore U, Patro P, Agarwal V, Sharma A. Corticosteroid monotherapy for the management of Takayasu arteritis-a systematic review and meta analysis. Rheumatol Int. 2021;41:1729\u201342.","journal-title":"Rheumatol Int"},{"key":"5009_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/BOR.0b013e3282f51031","volume":"20","author":"AK McDonough","year":"2008","unstructured":"McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol. 2008;20:131\u20137.","journal-title":"Curr Opin Rheumatol"},{"key":"5009_CR12","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s40265-014-0282-9","volume":"74","author":"L Fardet","year":"2014","unstructured":"Fardet L, Feve B. Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events. Drugs. 2014;74:1731\u201345.","journal-title":"Drugs"},{"key":"5009_CR13","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/annrheumdis-2017-211878","volume":"77","author":"Y Nakaoka","year":"2021","unstructured":"Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomized, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2021;77:348\u201354.","journal-title":"Ann Rheum Dis"},{"key":"5009_CR14","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1093\/rheumatology\/kez630","volume":"59","author":"Y Nakaoka","year":"2020","unstructured":"Nakaoka Y, Isobe M, Tanaka Y, Ishii T, Ooka S, Niiro H, et al. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. Rheumatology (Oxford). 2020;59:2427\u201334.","journal-title":"Rheumatology (Oxford)"},{"key":"5009_CR15","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/art.40037","volume":"69","author":"CA Langford","year":"2017","unstructured":"Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis. Arthritis Rheumatol. 2017;69:846\u201353.","journal-title":"Arthritis Rheumatol"},{"key":"5009_CR16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.imbio.2016.10.008","volume":"222","author":"G Shi","year":"2017","unstructured":"Shi G, Hua M, Xu Q, Ren T. Resveratrol improves treatment outcome and laboratory parameters in patients with Takayasu arteritis: a randomized double-bind placebo-controlled trial. Immunobiology. 2017;222:164\u20138.","journal-title":"Immunobiology"},{"key":"5009_CR17","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s12026-017-8917-z","volume":"65","author":"N Shao","year":"2017","unstructured":"Shao N, Jia H, Li Y, Li J. Curcumin improves treatment outcome of Takayasu arteritis patients by reducing TNF-alpha: a randomized placebo-controlled double-blind clinical trial. Immunol Res. 2017;65:969\u201374.","journal-title":"Immunol Res"},{"key":"5009_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/mr\/roac157","volume":"34","author":"S Padiyar","year":"2023","unstructured":"Padiyar S, Danda D, Goel R, Joseph E, Nair AM, Joseph G, et al. Clinical and angiographic outcomes of mycophenolate versus methotrexate in South Asian patients with Takayasu arteritis: results from an open-label, outcome-assessor blinded randomized controlled trial. Mod Rheumatol. 2023;34:175\u201381.","journal-title":"Mod Rheumatol"},{"key":"5009_CR19","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.ard.2025.07.018","volume":"84","author":"X Sun","year":"2025","unstructured":"Sun X, Li J, Duan X, Wang Y, Chen Y, Wang Y, et al. Mycophenolate mofetil plus methotrexate versus cyclophosphamide with sequential azathioprine for treatment of Takayasu arteritis. Ann Rheum Dis. 2025;84:1733\u201342.","journal-title":"Ann Rheum Dis"},{"key":"5009_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/1756-185X.14491","volume":"26","author":"K Zheng","year":"2023","unstructured":"Zheng K, Chen Y, Liu S, He C, Yang Y, Wu D, et al. Leflunomide: traditional immunosuppressant with concurrent antiviral effects. Int J Rheum Dis. 2023;26:195\u2013209.","journal-title":"Int J Rheum Dis"},{"key":"5009_CR21","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/rheumatology\/keh500","volume":"44","author":"P Maddison","year":"2005","unstructured":"Maddison P, Kiely P, Kirkham B, Lawson T, Moots R, Proudfoot D, et al. Leflunomide in rheumatoid arthritis: recommendation through a process of consensus. Rheumatology (Oxford). 2005;44:280\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"5009_CR22","doi-asserted-by":"publisher","first-page":"102960","DOI":"10.1016\/j.autrev.2021.102960","volume":"21","author":"I Carri\u00f3n-Barber\u00e0","year":"2022","unstructured":"Carri\u00f3n-Barber\u00e0 I, Polino L, Mej\u00eda-Torres M, P\u00e9rez-Garc\u00eda C, Ciria M, Pros A, et al. Leflunomide: a safe and effective alternative in systemic lupus erythematosus. Autoimmun Rev. 2022;21:102960.","journal-title":"Autoimmun Rev"},{"key":"5009_CR23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.55563\/clinexprheumatol\/ve38dj","volume":"Suppl 129","author":"N Mustapha","year":"2021","unstructured":"Mustapha N, Barra L, Carette S, Cuthbertson D, Khalidi NA, Koening CL, et al. Efficacy of leflunomide in the treatment of vasculitis. Clin Exp Rheumatol. 2021;Suppl 129:114\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"5009_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3109\/03009742.2011.633553","volume":"41","author":"AW de Souza","year":"2012","unstructured":"de Souza AW, da Silva MD, Machado LS, Oliveira AC, Pinheiro FA, Sato EI. Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. Scand J Rheumatol. 2012;41:227\u201330.","journal-title":"Scand J Rheumatol"},{"key":"5009_CR25","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.rbr.2015.09.007","volume":"56","author":"AW de Souza","year":"2016","unstructured":"de Souza AW, de Almeida Agustinelli R, de Cinque Almeida H, Oliveira PB, Pinheiro FA, Oliveira AC, et al. Leflunomide in Takayasu arteritis-a long term observational study. Rev Bras Rheumatol Engl Ed. 2016;56:371\u20135.","journal-title":"Rev Bras Rheumatol Engl Ed"},{"key":"5009_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.semarthrit.2019.06.009","volume":"50","author":"X Cui","year":"2020","unstructured":"Cui X, Dai X, Ma L, Yang C, Tan W, Zhang L, et al. Efficacy and safety of leflunomide treatment in Takayasu arteritis: case series from the East China cohort. Semin Arthritis Rheum. 2020;50:59\u201365.","journal-title":"Semin Arthritis Rheum"},{"key":"5009_CR27","doi-asserted-by":"publisher","first-page":"204062232097523","DOI":"10.1177\/2040622320975233","volume":"11","author":"C Wu","year":"2020","unstructured":"Wu C, Sun Y, Cui X, Wu S, Ma L, Chen H, et al. Effectiveness and safety of methotrexate versus leflunomide in 12-month treatment for Takayasu arteritis. Ther Adv Chronic Dis. 2020;11:2040622320975233.","journal-title":"Ther Adv Chronic Dis"},{"key":"5009_CR28","doi-asserted-by":"publisher","first-page":"1759720X2093011","DOI":"10.1177\/1759720X20930114","volume":"12","author":"S Ying","year":"2020","unstructured":"Ying S, Xiaomeng C, Xiaomin D, Jiang L, Peng L, Lili M, et al. Efficacy and safety of leflunomide versus cyclophosphamide for initial-onset Takayasu arteritis: a prospective cohort study. Ther Adv Musculoskelet Dis. 2020;12:1759720X20930114.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"5009_CR29","doi-asserted-by":"publisher","first-page":"204062232092201","DOI":"10.1177\/2040622320922019","volume":"11","author":"X Dai","year":"2020","unstructured":"Dai X, Cui X, Sun Y, Ma L, Jiang L. Effectiveness and safety of leflunomide compared with cyclophosphamide as induction therapy in Takayasu\u2019s arteritis: an observational study. Ther Adv Chronic Dis. 2020;11:2040622320922019.","journal-title":"Ther Adv Chronic Dis"},{"key":"5009_CR30","doi-asserted-by":"publisher","first-page":"152018","DOI":"10.1016\/j.semarthrit.2022.152018","volume":"55","author":"J Wang","year":"2022","unstructured":"Wang J, Dai X, Ma L, Wu S, Jin X, Ji Z, et al. Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: a prospective study. Semin Arthritis Rheum. 2022;55:152018.","journal-title":"Semin Arthritis Rheum"},{"key":"5009_CR31","doi-asserted-by":"publisher","first-page":"e003992","DOI":"10.1136\/rmdopen-2023-003992","volume":"10","author":"F Peron Filho","year":"2024","unstructured":"Peron Filho F, Moreira AS, Janes ALF, de Souza AWS. Effectiveness and safety of adalimumab compared with leflunomide in patients with Takayasu arteritis: a retrospective cohort study. RMD Open. 2024;10:e003992.","journal-title":"RMD Open"},{"key":"5009_CR32","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/art.1780330811","volume":"33","author":"WP Arend","year":"1990","unstructured":"Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33:129\u201334.","journal-title":"Arthritis Rheum"},{"key":"5009_CR33","doi-asserted-by":"publisher","first-page":"919","DOI":"10.7326\/0003-4819-120-11-199406010-00004","volume":"120","author":"GS Kerr","year":"1994","unstructured":"Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Ann Intern Med. 1994;120:919\u201329.","journal-title":"Ann Intern Med"},{"key":"5009_CR34","doi-asserted-by":"crossref","unstructured":"Hata A, Noda M, Moriwaki R, Numano F. Angiographic findings of Takayasu arteritis: new classification. Int J Cardiol. 1996; 54 Suppl: 155\u2013163.","DOI":"10.1016\/S0167-5273(96)02813-6"},{"key":"5009_CR35","doi-asserted-by":"publisher","first-page":"152446","DOI":"10.1016\/j.semarthrit.2024.152446","volume":"66","author":"S Kaymaz-Tahra","year":"2024","unstructured":"Kaymaz-Tahra S, Bayindir O, Ince B, Ozdemir Isik O, Kutu ME, Karakas O, et al. Comparison of methotrexate and azathioprine as the first-line steroid-sparing immunosuppressive agents in patients with Takayasu\u2019s arteritis. Semin Arthritis Rheum. 2024;66:152446.","journal-title":"Semin Arthritis Rheum"},{"key":"5009_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/annrheumdis-2021-220832","volume":"81","author":"X Kong","year":"2022","unstructured":"Kong X, Sun Y, Dai X, Wang L, Ji Z, Chen H, et al. Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study. Ann Rheum Dis. 2022;81:117\u201323.","journal-title":"Ann Rheum Dis"},{"key":"5009_CR37","doi-asserted-by":"publisher","first-page":"e002830","DOI":"10.1136\/rmdopen-2022-002830","volume":"9","author":"A Mekinian","year":"2023","unstructured":"Mekinian A, Biard L, Lorenzo D, Novikov PI, Salvarani C, Espitia O, et al. Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study. RMD Open. 2023;9:e002830.","journal-title":"RMD Open"},{"key":"5009_CR38","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1093\/rheumatology\/kead387","volume":"63","author":"J Wang","year":"2024","unstructured":"Wang J, Kong X, Ma L, Ding Z, Chen H, Chen R, et al. Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis: an open-label study. Rheumatology (Oxford). 2024;63:1359\u201367.","journal-title":"Rheumatology (Oxford)"},{"key":"5009_CR39","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1093\/rheumatology\/keab635","volume":"61","author":"A Mekinian","year":"2022","unstructured":"Mekinian A, Biard L, Dagna L, Novikov P, Salvarani C, Espitia O, et al. Efficacy and safety of TNF-alpha antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. Rheumatology (Oxford). 2022;61:1376\u201384.","journal-title":"Rheumatology (Oxford)"},{"key":"5009_CR40","doi-asserted-by":"publisher","first-page":"1174249","DOI":"10.3389\/fimmu.2023.1174249","volume":"14","author":"DP Misra","year":"2023","unstructured":"Misra DP, Singh K, Sharma A, Agarwal V. Arterial wall fibrosis in Takayasu arteritis and its potential for therapeutic modulation. Front Immunol. 2023;14:1174249.","journal-title":"Front Immunol"},{"key":"5009_CR41","unstructured":"Cui X, Kong X, Chen R, Ma L, Jiang L. The potential role of leflunomide in inhibiting vascular fibrosis by down-regulating type-II macrophages in Takayasu\u2019s arteritis. Clin Exp Rheumatol. 2020;Suppl 124:69\u201378."},{"key":"5009_CR42","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.trsl.2022.12.004","volume":"255","author":"X Dai","year":"2023","unstructured":"Dai X, Sun Y, Ma L, Hou J, Wang L, Gong Y, et al. A novel molecular mechanism of vascular fibrosis in Takayasu arteritis: macrophage-derived GPNMB promoting adventitial fibroblast extracellular matrix production in the aorta. Transl Res. 2023;255:128\u201339.","journal-title":"Transl Res"},{"key":"5009_CR43","doi-asserted-by":"publisher","first-page":"103277","DOI":"10.1016\/j.jaut.2024.103277","volume":"148","author":"J Wang","year":"2024","unstructured":"Wang J, Sun Y, Chen R, Meng D, Wei Y, Jiang L, et al. Pro-fibrotic effect of the susceptible gene PCSK5 in vascular fibrosis of Takayasu arteritis via TGF-beta and SMAD3 signaling pathway activation. J Autoimmun. 2024;148:103277.","journal-title":"J Autoimmun"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-05009-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05009-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05009-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:16:43Z","timestamp":1791339403000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-05009-1"}},"subtitle":["Takayasu arteritis clinical trial in China (TACTIC)"],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5009"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-05009-1","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial was approved by the Ethics Committee of Zhongshan Hospital, Fudan University (Shanghai, China; approval number: B2016-151). Written informed consent was obtained from all participants prior to enrolment.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"549"}}